Paradigm Biopharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de Paradigm Biopharmaceuticals ont diminué à un taux annuel moyen de -29.1%, tandis que le secteur Biotechs a vu ses bénéfices augmenter de en à 12.6% par an. Les revenus ont augmenté de en baisse à un taux moyen de 73.9% par an.

Informations clés

-29.1%

Taux de croissance des bénéfices

-19.5%

Taux de croissance du BPA

Biotechs Croissance de l'industrie	9.6%
Taux de croissance des recettes	-73.9%
Rendement des fonds propres	-246.4%
Marge nette	n/a
Dernière mise à jour des bénéfices	30 Jun 2024

Mises à jour récentes des performances passées

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

Ventilation des recettes et des dépenses

Comment Paradigm Biopharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.

Historique des gains et des recettes

ASX:PAR Recettes, dépenses et bénéfices (AUD Millions )
Date	Recettes	Les revenus	Dépenses G+A	Dépenses de R&D
30 Jun 24	0	-59	7	58
31 Mar 24	0	-64	6	65
31 Dec 23	0	-69	6	71
30 Sep 23	0	-60	7	62
30 Jun 23	0	-52	7	53
31 Mar 23	0	-48	9	48
31 Dec 22	0	-44	10	43
30 Sep 22	0	-42	9	41
30 Jun 22	0	-39	9	39
31 Mar 22	0	-40	9	39
31 Dec 21	0	-41	10	40
30 Sep 21	0	-37	10	37
30 Jun 21	0	-34	10	34
31 Mar 21	0	-31	7	30
31 Dec 20	-1	-28	5	27
30 Sep 20	0	-20	4	20
30 Jun 20	0	-12	3	14
31 Mar 20	2	-14	4	12
31 Dec 19	4	-16	4	9
30 Sep 19	3	-16	4	8
30 Jun 19	3	-16	4	8
31 Mar 19	3	-11	3	7
31 Dec 18	3	-7	3	7
30 Sep 18	3	-7	2	7
30 Jun 18	3	-6	2	7
31 Mar 18	2	-6	2	6
31 Dec 17	2	-5	2	5
30 Sep 17	2	-5	2	5
30 Jun 17	2	-4	2	4
31 Mar 17	2	-4	2	4
31 Dec 16	1	-4	2	4
30 Sep 16	1	-4	2	3
30 Jun 16	1	-3	1	3
31 Mar 16	1	-3	2	2
31 Dec 15	0	-2	1	1
30 Sep 15	0	-2	1	1
30 Jun 15	0	-2	1	0

Des revenus de qualité: PAR n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: PAR n'est actuellement pas rentable.

Analyse des flux de trésorerie disponibles par rapport aux bénéfices

Analyse de la croissance passée des bénéfices

Tendance des revenus: PAR n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 29.1% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de PAR au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: PAR n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Biotechs ( 2.6% ).

Rendement des fonds propres

ROE élevé: PAR a un retour sur capitaux propres négatif ( -246.38% ), car il n'est actuellement pas rentable.

Paradigm Biopharmaceuticals Résultats passés

Passé contrôle des critères 0/6

Informations clés

Mises à jour récentes des performances passées

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

New 90-day low: AU$2.38

New 90-day low: AU$2.44

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Paradigm Biopharmaceuticals Ltd Receives the Written Response from the Type-C meeting with the US Food and Drug Administration (FDA) regarding Zilosul® for the Treatment of Osteoarthritis

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director

New 90-day high: AU$3.13

Paradigm Biopharmaceuticals Limited Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating PPS in Mucopulysaccharidoses Type-1

Paradigm Biopharmaceuticals Limited Adds Senior Executives to its Team

Paradigm Biopharmaceuticals Ltd Clear Path Towards Zilosul's Oa Phase 3 Clinical Trial and Product Registration in Europe

Paradigm Biopharmaceuticals Ltd Reports Additional Data on Patients Who Received Zilosul® Under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS)